{"id":262807,"date":"2025-01-31T14:29:23","date_gmt":"2025-01-31T13:29:23","guid":{"rendered":"https:\/\/sola-diagnostics.com\/?page_id=262807"},"modified":"2026-04-06T13:17:40","modified_gmt":"2026-04-06T12:17:40","slug":"about","status":"publish","type":"page","link":"https:\/\/sola-diagnostics.com\/en\/about\/","title":{"rendered":"About"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Submen\u00fc” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#7F5E75″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” sticky_position=”top” sticky_position_tablet=”none” sticky_position_phone=”none” sticky_position_last_edited=”on|phone” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”10px||10px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”Georgia||||||||” text_text_color=”#FFFCFC” text_font_size=”16px” link_text_color=”#FFFCFC” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

Vision & Mission<\/a> | Value Proposition<\/a> | Leadership Team<\/a> | Milestones<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Herosection” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” width=”100%” module_alignment=”center” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/header_about.png” title_text=”header_about” show_bottom_space=”off” align=”center” force_fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Vision & Mission” module_id=”en_a_vision_mission” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Vision” admin_label=”Heading – Vision” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ title_text_align=”center” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”23px” text_line_height=”1.8em” text_orientation=”center” custom_margin=”||||false|false” locked=”off” global_colors_info=”{}”]<\/p>\n

Our vision is to lead a global transformation in women\u2019s cancer prevention and early diagnosis by making innovative, accessible, and personalized solutions the Standard Of Care\u2014empowering women worldwide to live healthier lives.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Mission” admin_label=”Heading – Vision” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ title_text_align=”center” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”23px” text_line_height=”1.8em” text_orientation=”center” custom_margin=”||||false|false” locked=”off” global_colors_info=”{}”]<\/p>\n

Our mission is to address unmet needs in women\u2019s cancer prevention and diagnosis by delivering personalized care through innovative epigenetic solutions, driving global access to improve outcomes for women across the globe.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#7F5E75″ divider_position=”center” divider_weight=”2px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Value Proposition” module_id=”en_a_value_proposition” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row module_id=”Prinzip” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Value Proposition” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

At Sola Dx, we are revolutionising personalised primary and secondary prevention through ground-breaking innovations, including the WID\u00ae-easy Test for the early detection of endometrial cancer and the WID\u00ae-can Test for cervical cancer risk prediction.<\/p>\n

Our key focus is driving the rapid adoption of the WID\u00ae-easy Test among symptomatic women in major global markets, laying the groundwork for population-wide screening and unlocking substantial market potential.<\/p>\n

The WID\u00ae-can Test is poised to redefine cervical cancer screening as a non-cytology molecular triage tool. Unlike traditional methods reliant on cellular morphology, the WID\u00ae-can Test can be performed on self-collected samples, offering superior objectivity, reproducibility, and accessibility compared to current standards.<\/p>\n

The WID\u00ae-ok Test is designed to identify women at high risk for ovarian cancer, regardless of genetic predisposition. By detecting risk factors beyond hereditary mutations, the WID\u00ae-ok Test enables proactive prevention, offering a crucial opportunity to intervene before this highly lethal disease develops.<\/p>\n

The WID\u00ae-best Test represents a breakthrough in breast cancer risk stratification by leveraging an epigenetic signature detected in cervical smear samples. This cutting-edge test identifies women at heightened risk of developing breast cancer, enabling personalized primary prevention strategies and facilitating risk-adjusted screening protocols.<\/p>\n

Through our unwavering commitment to innovation, we are addressing the critical diagnostic needs of women today while paving the way for a future where personalized, accessible, and effective cancer prevention becomes the global Standard Of Care.<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”What We Do” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

We develop and market minimally invasive epigenetic diagnostic tools, including the WID\u00ae-easy and WID\u00ae-can Tests, designed to detect gynaecological cancers at an early stage, when treatments are most effective, and success rates are highest. Leveraging the same cervico-vaginal sample, we are pioneering the development of adaptable epigenetic risk markers, such as the WID\u00ae-best Test, with the potential to enable personalized prevention strategies for other women\u2019s cancers as well.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Why We’re Different” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

At Sola Dx, we are a commercial-stage epigenetic diagnostics company built on over 30 years of ground-breaking research in DNA methylation and gynaecological cancers. Our technologies originate from the pioneering work of Prof. Martin Widschwendter<\/a> and his world-renowned academic team. Leveraging cutting-edge epigenetic science, we develop diagnostic tests that are both highly accurate and minimally invasive. By focusing on tailored precision prevention, we empower women with the knowledge and tools to make better informed health decisions, setting us apart as leaders in women\u2019s health diagnostics.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#7F5E75″ divider_position=”center” divider_weight=”2px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Leadership” module_id=”en_a_leadership” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”off” global_colors_info=”{}”][et_pb_row admin_label=”Row” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Leadership Team” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_heading title=”Advisory Council (Beirat)” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.27.4″ _module_preset=”default” module_alignment=”center” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Hon. Prof. Adeola Olaitan” position=”Advisor for Gynaecological Oncology” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/04\/Adeola_Olaitan.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/adeola-olaitan-788a2448\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Nora Pashayan” position=”Advisor for Risk-Stratified Cancer Screening” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/04\/Nora_Pashayan.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/nora-pashayan-bb980545\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Silvia de Sanjos\u00e9” position=”Advisor for Viral Oncology and Epidemiology” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/04\/Platzhalter.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/silvia-de-sanjose-92083531\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.27.4″ _module_preset=”default” module_alignment=”center” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Martin Widschwendter” position=”Executive Chair, Founder” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/widschwendter.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/martin-widschwendter-66453b3b\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Angus MacLennan” position=”Non-Executive Chair” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/04\/Advisory_Board_Angus.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/angus-maclennan-2b75b514\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Mag. Manfred Pletzer” position=”Member of the Board, Investor” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/pletzer.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/manfred-pletzer-533231294\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Row” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Executive Team” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Martin Widschwendter” position=”Chief Executive Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/widschwendter.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/martin-widschwendter-66453b3b\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.4″ _module_preset=”default” border_color_all=”#7F5E75″ global_colors_info=”{}”]<\/p>\n

Prof. Martin Widschwendter is the founder and Chief Executive Officer of Sola Diagnostics.<\/strong><\/p>\n

A globally recognized expert in women\u2019s health diagnostics with over 30 years of pioneering research in DNA methylation and gynecological cancers, he combines scientific excellence with strategic leadership. As CEO, Prof. Widschwendter drives the company\u2019s mission to transform cancer prevention and early detection through epigenetics. His groundbreaking work underpins Sola Diagnostics\u2019 core technologies, including the WID\u00ae-easy, WID\u00ae-can, and WID\u00ae-best Tests. With a unique ability to translate academic innovation into impactful clinical solutions, he ensures that Sola Diagnostics remains at the forefront of precision diagnostics and women\u2019s health.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Dr. Peter Kayatz” position=”Chief Commercial Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/kayatz.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/kayatz\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.4″ _module_preset=”default” border_color_all=”#7F5E75″ global_colors_info=”{}”]<\/p>\n

Dr. Peter Kayatz is the Chief Commercial Officer of Sola Diagnostics.<\/b><\/b><\/p>\n

With over 20 years of experience in life sciences management and business strategy, he leads the company\u2019s global commercial activities, including business development, strategic partnerships, and market expansion. Dr. Kayatz is dedicated to bringing innovative diagnostic solutions to market that address critical unmet needs in women\u2019s health. Drawing on a strong track record in leadership roles across biotech and diagnostic companies, he combines strategic insight with operational execution to drive the commercial success of Sola Diagnostics and support its long-term growth.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Sara Sleigh, PhD” position=”Chief Development Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/sleigh.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/sara-sleigh-4a95954\/” disabled_on=”off|off|off” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}”][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.4″ _module_preset=”default” border_color_all=”#7F5E75″ global_colors_info=”{}”]<\/p>\n

Dr. Sara Sleigh oversees clinical development at Sola Diagnostics, managing the design, execution, and regulatory approval of clinical trials for the company\u2019s diagnostic products. With extensive experience in clinical research and development, she ensures that Sola\u2019s solutions meet regulatory requirements and demonstrate clinical efficacy. Dr. Sleigh\u2019s leadership drives the transition of diagnostic innovations, like the WID\u00ae-easy and WID\u00ae-best Tests, from research to real-world application. Her commitment to advancing women\u2019s health through evidence-based diagnostics positions Sola Diagnostics as a trusted partner in the field of gynecological and breast cancer prevention.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Mag. David Tschabitscher” position=”Chief Operating Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/tschabitscher.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/david-tschabitscher\/” _builder_version=”4.27.6″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.6″ _module_preset=”default” hover_enabled=”0″ border_color_all=”#7F5E75″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n
\n
\n
\n

Mag. David Tschabitscher is the Chief Operating Officer at Sola Diagnostics, responsible for IT infrastructure, process optimization, and quality management. With a strong background in entrepreneurship and operational leadership, he drives the systems and structures that enable Sola’s innovative diagnostic solutions to scale. David oversees the company’s QMS, ensuring regulatory compliance and operational excellence across all functions \u2014 positioning Sola as a trusted leader in women’s health diagnostics.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Elisa Redl, PhD” position=”Head of Analytical Development” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/redl.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/elisa-redl-50128b226\/” _builder_version=”4.27.4″ _module_preset=”default” position_text_align=”center” text_orientation=”center” custom_margin=”||||false|false” custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}”][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.4″ _module_preset=”default” border_color_all=”#7F5E75″ global_colors_info=”{}”]<\/p>\n

Dr. Elisa Redl is the Head of Analytical Development at Sola Diagnostics, where she ensures the scientific rigor and technical accuracy of the company\u2019s diagnostic assays. With a PhD in molecular diagnostics, she specializes in assay development, validation, and optimization for innovative diagnostic tools. Dr. Redl plays a critical role in advancing the technical capabilities of the WID\u00ae-easy, WID\u00ae-can, and WID\u00ae-best Tests. Her expertise ensures that Sola Diagnostics\u2019 products meet the highest standards of analytical performance, enabling precise and reliable results. Dr. Redl is passionate about translating science into impactful solutions for women\u2019s health.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Dr. Chiara Herzog” position=”Head of Epigenetic Biomarker Innovation” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/07\/chiara.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/chiara-herzog\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.4″ _module_preset=”default” border_color_all=”#7F5E75″ global_colors_info=”{}”]<\/p>\n

Dr. Chiara Herzog is Head of Epigenetic Biomarker Innovation at Sola Diagnostics, where she contributes to the scientific direction of DNA methylation-based diagnostics. An expert in translational epigenetics with a background in molecular medicine, she has authored seminal papers and contributed to key intellectual property underpinning Sola\u2019s biomarker portfolio, including the WID\u00ae-easy and WID\u00ae-can Tests. Dr. Herzog also plays an active role in international consortia advancing biomarker standards, helping bridge academic discovery and clinical implementation in women\u2019s health and ageing research.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”James Barrett, PhD” position=”Head of Statistics & Bioinformatics” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/barrett.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/james-e-barrett-71064685\/” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][\/et_pb_team_member][et_pb_toggle title=”More” open_toggle_background_color=”#FFFCFC” closed_toggle_background_color=”#FFFCFC” icon_color=”#7F5E75″ toggle_icon=”G||divi||400″ open_icon_color=”#7F5E75″ open_toggle_icon=”F||divi||400″ _builder_version=”4.27.4″ _module_preset=”default” border_color_all=”#7F5E75″ global_colors_info=”{}”]<\/p>\n

Dr. James Barrett leads statistical and bioinformatics strategies at Sola Diagnostics, ensuring the robustness and reliability of the company\u2019s data-driven insights. With a PhD in bioinformatics and extensive experience in statistical modeling, he plays a pivotal role in developing algorithms and methodologies that underpin the performance of the WID\u00ae-easy, WID\u00ae-can, and WID\u00ae-best Tests. Dr. Barrett\u2019s expertise ensures that the company\u2019s diagnostic solutions are validated through rigorous analysis, delivering reliable and actionable results for patients and clinicians. His work enables Sola Diagnostics to maintain its position at the forefront of precision medicine.<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Our Impact” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

Our innovative diagnostics are designed to reduce morbidity and mortality from women\u2019s cancers through precision prevention and early detection.<\/p>\n

The WID\u00ae-easy Test minimises the need for unnecessary surgical procedures, lowering healthcare costs, protecting women from invasive interventions, and enhancing the effectiveness of early cancer detection.<\/p>\n

The WID\u00ae-can Test benefits patients by offering an accessible, minimally invasive cervical cancer screening solution that can be performed on self-collected samples, reducing discomfort, increasing accessibility, and delivering more accurate and reproducible results.<\/p>\n

The WID\u00ae-best Test empowers women by identifying their elevated risk of breast cancer through minimally invasive analysis of cervical smear samples, enabling personalized prevention strategies and proactive health management.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Our Values” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

    \n
  • Patient-Focussed:<\/strong> We prioritize the well-being and needs of women, ensuring our diagnostic solutions are accessible, minimally invasive, and designed to improve patient outcomes.<\/li>\n
  • Scientific Excellence:<\/strong> Our work is grounded in over 30 years of pioneering research in DNA methylation and women’s cancers, led by Prof. Martin Widschwendter.<\/li>\n
  • Innovation:<\/strong> We leverage cutting-edge epigenetic research to develop advanced precision prevention tests that are both highly accurate and minimally invasive.<\/li>\n
  • Integrity:<\/strong> We uphold the highest ethical standards in our research, partnerships, and operations.<\/li>\n
  • Collaboration:<\/strong> We work with global partners to expand access and improve outcomes in women\u2019s health diagnostics.<\/li>\n
  • Empowerment:<\/strong> We provide women with the knowledge and tools to take charge of their health and well-being.<\/li>\n<\/ul>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#7F5E75″ divider_position=”center” divider_weight=”2px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Milestones” module_id=”en_a_milestones” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Milestones” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”2020″ _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

      \n
    • Sola Diagnostics GmbH was established by Prof. Martin Widschwendter in Tyrol, Austria, leveraging decades of expertise in epigenetic research.<\/li>\n<\/ul>\n

      [\/et_pb_text][et_pb_heading title=”2021″ _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

        \n
      1. Licensing agreement with the University College London<\/li>\n
      2. Convertible Loan by the University of Innsbruck<\/li>\n<\/ol>\n

        [\/et_pb_text][et_pb_heading title=”2022″ _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

          \n
        1. \n
          Equity Financing by a consortium of four Tyrolean business angels<\/div>\n<\/li>\n
        2. \n
          The development and initial validation of WID\u00ae-easy, WID\u00ae-can, and WID\u00ae-best have been published in leading scientific journals, including the Journal of Clinical Oncology, Clinical Epigenetics, and Nature Communications.<\/div>\n

           <\/p>\n<\/li>\n<\/ol>\n

          [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”2023″ _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

            \n
          • WID\u00ae-easy Test\u2019s performance published in The Lancet Oncology<\/li>\n<\/ul>\n

            [\/et_pb_text][et_pb_heading title=”2024″ _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|600|||||||” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

              \n
            1. \n
              WID\u00ae-easy Test launched in Austria and Switzerland<\/div>\n<\/li>\n
            2. \n
              WID\u00ae-can Test’s performance published in Nature Medicine<\/div>\n<\/li>\n
            3. \n
              WID\u00ae-easy Test UKCA-marked<\/div>\n<\/li>\n<\/ol>\n

              [\/et_pb_text][et_pb_heading title=”2025″ _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” text_font=”|600|||||||” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

                \n
              • WID\u00ae-easy Test launched in the UK<\/li>\n
              • WID\u00ae-easy Test launched in Germany<\/li>\n<\/ul>\n

                [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#7F5E75″ divider_position=”center” divider_weight=”2px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Call to Action” module_id=”en_d_benefit” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Join us in our mission to revolutionise women\u2019s health. Explore our innovative solutions or contact us to learn more about how we\u2019re making a world of difference.” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ title_text_align=”center” title_font_size=”41px” title_line_height=”1.2em” title_font_size_tablet=”41px” title_font_size_phone=”20px” title_font_size_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

                Vision & Mission | Value Proposition | Leadership Team | MilestonesOur vision is to lead a global transformation in women\u2019s cancer prevention and early diagnosis by making innovative, accessible, and personalized solutions the Standard Of Care\u2014empowering women worldwide to live healthier lives.Our mission is to address unmet needs in women\u2019s cancer prevention and diagnosis by […]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-262807","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/262807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/comments?post=262807"}],"version-history":[{"count":7,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/262807\/revisions"}],"predecessor-version":[{"id":264011,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/pages\/262807\/revisions\/264011"}],"wp:attachment":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media?parent=262807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}